Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Equity Ratio (2019 - 2025)

Vivos Therapeutics' Equity Ratio history spans 7 years, with the latest figure at 0.06 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.06 for Q4 2025, down 111.38% from a year ago — trailing twelve months through Dec 2025 was 0.06 (down 111.38% YoY), and the annual figure for FY2025 was 0.06, down 111.38%.
  • Equity Ratio for Q4 2025 was 0.06 at Vivos Therapeutics, down from 0.1 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.79 in Q3 2021 to a low of 0.06 in Q4 2025.
  • The 5-year median for Equity Ratio is 0.4 (2023), against an average of 0.39.
  • The sharpest move saw Equity Ratio soared 11101.71% in 2024, then tumbled 111.38% in 2025.
  • Year by year, Equity Ratio stood at 0.76 in 2021, then tumbled by 53.84% to 0.35 in 2022, then tumbled by 89.05% to 0.04 in 2023, then skyrocketed by 1258.65% to 0.52 in 2024, then tumbled by 111.38% to 0.06 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.06, 0.1, and 0.18 for Q4 2025, Q3 2025, and Q2 2025 respectively.